

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 26/08/2022

To,
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange
P.J. Towers, Dalal Street
Mumbai - 400 001.

Ref: Scrip Code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52(4), 54(2) of Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir/Ma'am,

With reference to the subject matter, Please find enclosed the following:

- i. The Audited Standalone Financial Results of the Company for Financial Year ended 31st March 2022 along with the Unaudited Standalone Financial Results for Quarter ended 31st March 2022 and the Auditors Report for that period issued by the Statutory Auditors under SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52 (4) of SEBI (LODR), 2015
- iii. A disclosure under Regulation 54 (2) of SEBI (LODR), 2015.
- iv. Declaration of unmodified opinion pursuant to Regulation 52(3)(a) of SEBI (LODR), 2015

Please take the above information on your records.

For and on behalf of
For Genlink Pharma Solutions Private Limited

Anand Shah
Director
DIN: 00597145



INDEPENDENT AUDITOR'S REPORT

To The Members of
Genlink Pharma Solutions Private Limited
Mumbai

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying financial statements of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at March 31, 2022, the Statement of Profit and Loss, the Cash Flow Statement for the year then ended and Notes to the Financial Statements, including a summary of Significant Accounting Policies and other explanatory information (herein after referred to as "the Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2022, its Profit and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit of the Financial Statements in accordance with standard on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statement section of our report. We are independent of the company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules made there under and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained are sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Financial Statements of the current year. These matters were addressed in the context of our audit of the financial statement as whole and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.





Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of management and those charged with governance for the financial statements

The Company's board of directors are responsible for the matters stated in section 134 (5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The board of directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered





material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our



report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2022 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

A. As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
- c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account
- d) In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in Annexure B. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
- g) With respect to the other matters to be included in the auditor's report in accordance with the requirements of section 197(16) of the Act (as amended), we report that in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act; and
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position and its financial statements as of March 31, 2022.



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses; and
- iii. There were no amount which were required to be transferred, to the Invest or Education and Protection Fund by the Company.
- iv.(a) Management has represented to us that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ('Intermediaries'), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entities ('Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clauses (i) and (ii) of rule 11(e), as provided under (a) and (b) above, contain any material misstatement.



Place: Mumbai

Date: 26-08-2022

For Shankarlal Jain & Associates LLP
Chartered Accountants
Firm Registration No. 109901W/W100082

SATISH JAIN
Partner
Membership No. 048874
UDIN: 22048874APXSWF1024

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada,
Navi Mumbai, 400705, Maharashtra, India.

Standalone Statement of Assets and Liabilities as on 31st March, 2022

INR

Sr. No.	Particulars	As at year ended	As at year ended
		31/03/2022	31/03/2021
		Audited	Audited
I	ASSETS		
1	Non Current Assets		
	(a) Property, Plant & Equipment	2,88,97,971	2,94,09,414
	(b) Non Current Investments	24,89,95,479	24,89,95,479
2	Current Assets		
	(a) Trade receivables	-	26,254
	(b) Cash and cash equivalents	57,43,810	60,14,593
	(c) Loans & Advances	-	-
	(d) Other current assets	11,35,055	7,25,922
	TOTAL	28,47,72,315	28,51,71,661
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Share Capital	1,00,000	1,00,000
	(b) Reserves & Surplus	38,98,695	28,55,680
2	Non-Current Liabilities		
	(a) Long Term Borrowings	2,21,14,531	2,73,57,066
3	Current Liabilities		
	(a) Financial Liabilities		
	(i) Trade Payable	77,576	4,00,026
	(ii) Other Financial Liabilities	31,33,753	30,83,472
	(b) Short Term Borrowings	25,46,62,881	25,11,57,918
	(c) Current tax liabilities & provisions	2,57,500	2,17,500
	(c) Other Current Liabilities	5,27,379	-
	TOTAL	28,47,72,315	28,51,71,662

For Genlink Pharma Solutions Private Limited



Susheel Koul
Managing Director
DIN: 00925887

Anand Shah
Director
DIN: 00597145



Itishree Garg
Company Secretary &
Compliance officer
Membership no-
ACS 46259
Navi Mumbai
Date:

Place: Navi Mumbai

Date: 26/08/2022

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

Standalone Audited Financial Results for the Quarter and year ended 31st March, 2022

INR

Sr. No.	Particulars	Three months ended 31/03/2022	Preceding three months ended 31/12/2021	Year to date figures for current period ended 31/03/2022	Year to date Previous year ended 31/03/2021 and year ended 31/03/2021
		Unaudited	Unaudited	Audited	Audited
1	Income from Operations				
(i)	Net Sales/Income from Operations (Net of excise duty)	10,89,000	10,23,000	40,92,000	39,60,000
(ii)	Other Income	5,59,311	-	5,82,065	2,15,890
	Total Income from Operations	16,48,311	10,23,000	46,74,065	41,75,890
2	Expenses				
(i)	Cost of Material Consumed	-	-	-	-
(ii)	Purchase of Stock in trade	-	-	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-	-	-
(iv)	Employee Benefits Expenses	-	-	-	-
(v)	Depreciation and Amortization Expenses	1,26,109	1,28,912	5,11,443	5,11,443
(vi)	Finance Cost	(31,73,71,847)	5,35,055	21,65,206	21,77,234
(vii)	Other Expenses	2,28,625	2,05,625	7,80,200	9,53,156
	Total Expenses	(31,70,17,113)	8,69,592	34,56,849	36,41,833
3	Profit/(Loss) from operation before tax	31,86,65,424	1,53,409	12,17,216	5,34,057
4	Tax Expenses	55,500	48,600	1,74,200	1,75,700
5	Profit/(Loss) from ordinary activities for the period	31,86,09,924	1,04,809	10,43,016	3,58,357
6	Other Comprehensive Income				
(i)	Items that will not be reclassified to profit or loss	-	-	-	-
(ii)	Items that will be reclassified to profit or loss	-	-	-	-
	Total Comprehensive Income/(Loss) for the period	-	-	-	-
7	Paid up Equity Share Capital of 10/- each	1,00,000	1,00,000	1,00,000	1,00,000
8	Earning per Share(not annualised)				
	Basic	31,860.99	10.48	104	35.84
	Diluted				

For Genlink Pharma Solutions Private Limited



Susheel Koul
Managing Director

DIN: 00925887



Anand Shah
Director

DIN: 00597145



Itishree Garg
Company Secretary & Compliance Officer

Membership no- ACS 46259

Navi Mumbai

Date:

Place: Navi Mumbai

Date: 26/09/2022



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765


Regd Off. Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada,
Navi Mumbai, 400705, Maharashtra, India.


Statement of cash flow (standalone) for year ended 31st March, 2022

INR

Sr. No.	Particulars	As at year ended 31/03/2022	
		Audited	As at year ended 31/03/2021
		Audited	Audited
A	Cash flow from Operating Activities		
	(Loss) / Net profit before Taxation	12,17,216	5,34,057
	<u>Adjustment for:</u>		
	Interest and Finance Charges	21,65,206	21,77,234
	Depreciation and amortisation expenses	5,11,443	5,11,443
	Interest Income	(5,57,065)	-
	Operating Profit/(Loss) before working capital Changes	33,36,800	32,22,735
	<u>Adjustment for:</u>		
	Trade Receivables	26,254	6,27,696
	Short Term Loans and Advances	-	-
	Other Current Assets	32,190	(2,47,430)
	Other Long Liabilities	-	-
	Trade Payable	-	-
	Other Current Liabilities	2,95,210	(5,94,492)
	Provisions	-	42,500
	Cash Generated from/(Used) in Operating Activities	36,90,454	30,51,009
	Taxes Paid (net)	(1,92,024)	(3,29,692)
	Net Cash Flow from/(Used) in Operating Activities	34,98,430	27,21,317
B	Cash flow from Investing Activities		
	Purchase of Fixed assets	-	-
	Investments	-	-
	Sale of Fixed assets	-	-
	Loan given to Associates	-	-
	Interest Received	1,33,566	-
	(Purchases)/ Sale of Investments (Net)	-	-
	Increase in long term loans & advances	-	-
	Net Cash Flow from/(Used) in Investing Activities	1,33,566	-
C	Cash flow from Financing Activities		
	Dividend and DDT	-	-
	(Decrease) / Increase in Long term borrowings	(17,37,572)	54,67,947
	Proceeds from Short term borrowings	-	-
	Interest and Finance Charges	(21,65,206)	(21,77,234)
	Net Cash Flow from/(Used) in Financing Activities	(39,02,778)	32,90,713
	Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(2,70,782)	60,12,030
	Opening Cash and cash equivalent		
	Cash in Hand	67	67
	Balance in Current Account	60,14,526	2,496
	Balance in Fixed deposit Account	-	-
	Closing Cash and cash equivalent	60,14,593	2,563
	Cash in Hand	67	67
	Balance in Current Account	57,43,743	60,14,526
	Balance in Fixed deposit Account	-	-
	Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	57,43,810	60,14,593

For Genlink Pharma Solutions Private Limited


Sushel Koul
Managing Director
DIN: 00925887


Anand Shah
Director
DIN: 00597145


Itishree Garg
Company Secretary &
Compliance officer
Membership no-
ACS 46259
Navi Mumbai
Date:

Place: Navi Mumbai

Date: 26/08/2021

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

STATEMENT OF VALUE OF PLEDGED SECURITIES AS ON YEAR ENDED 31ST MARCH 2022

We hereby state that the Company maintains as on 31st March , 2022 such pledged securities as enlisted below:

1. 563,497 Equity Shares of Enaltec Labs Private Limited held by Genlink Pharma Solutions Private Limited at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
2. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Anand Shah at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.
3. 5,923 Equity Shares of Enaltec Labs Private Limited held by Mr. Susheel Koul at value of Rs. Nil per share vide Valuation Report by Vira Financial Advisors Private Limited aggregating to Rs. Nil.

For Genlink Pharma Solutions Private Limited

Anand Shah
Director
DIN: 00597145



Date: 26/08/2022
Place: Navi Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

With reference to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find disclosure as under for the Financial Year ended 31st March 2022.

1. **Debt-equity ratio - 69.22 times**
2. **Debt service coverage ratio - 0.01 times**
3. **Interest service coverage ratio - 1.81 times**
4. **Outstanding redeemable preference shares (quantity and value) - The Company does not have any outstanding redeemable preference shares.**
5. **Capital redemption reserve/debenture redemption reserve - Rs Nil.**
6. **Net worth - The net worth of the Company is Rs. 39,98,695/-**
7. **Net profit after tax**
Net profit after tax of the Company is Rs. 10,43,016/-
8. **Earnings per share**
Earnings per share of the Company is Rs. 104/-
9. **Current ratio - 3.06 times**
10. **Long term debt to working capital - NA**
11. **Bad debts to Account receivable ratio - NA**
12. **Current liability ratio - NA**
13. **Total debts to total assets - 0.97 times**
14. **Debtors turnover - 312 times**
15. **Inventory turnover - NA**
16. **Operating margin (%) - 26%**
17. **net profit margin (%) - 22%**



GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

18. Sector specific equivalent ratios, as applicable - NA

For Genlink Pharma Solutions Private Limited

Anand Shah
Director
DIN:00597145



Date: 26/08/2022
Place: Navi Mumbai

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 26/08/2022

To
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai-400001

Subject: Declaration pursuant to Regulation 52(3)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scrip Code: Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

Pursuant to Regulation 52(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, I Anand Shah, Director of Genlink Pharma Solutions Private Limited (Formerly Known as Genlink Pharma Investments Private Limited) (CIN: U74110MH2016PTC280765), having its Registered Office at Office No - 1701, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400705, Maharashtra, India, do hereby declare that, the Statutory Auditors of the Company, Shankarlal Jain & Associates LLP, Chartered Accountants (FRN 109901W/W100082) have issued an Audit Report with an unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2022.

Kindly take this declaration on record.

Yours faithfully,

For Genlink Pharma Solutions Private Limited

Anand Shah
Director
DIN: 00597145



Shankarlal Jain & Associates LLP**Chartered Accountants**

12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To
Stock Exchange (s)

Based on examination of books of accounts and other relevant records/documents, of **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN U74110MH2016PTC280765) having its registered office at 1701, 17th Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai - 400705, we hereby certify that:

- a) The listed entity has vide its Board Resolution and information memorandum/ offer document and under various Debenture Trust Deeds, has issued the following listed debt securities:

ISIN	Private Placement/ Public Issue	Secured/ Unsecured	Sanctioned Amount
INE988W07019	Private Placement	Secured	Rs. 25.00 Crore

b) **Asset Cover for listed debt securities:**

- i. The financial information as on **31st March 2022** has been extracted from the books of accounts for the year ended **31st March 2022** and other relevant records of the listed entity;
- ii. The assets of the entity provide coverage of **NIL times** of the interest and principal amount. (calculation as per statement of asset cover ratio for the Secured debt securities - table - I)
- iii. The total assets of the listed entity provide coverage of **Not Applicable** of the principal, which is in accordance with the terms of issue (calculation as per statement of asset coverage ratio available for the unsecured debt securities - table - II) (as per requirement of Regulation 54 read with Regulation 56(1)(d) of LODR Regulations).



Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

Table - I

Sr. No.	Particulars		Amount in Rs. Crore
i.	Total assets available for secured Debt Securities' - (secured by either pari passu or exclusive charge on assets) (mention the share of Debt Securities' charge holders)	A	*NIL Please refer note
	• Property Plant & Equipment (Fixed assets) - movable/immovable property, etc.		Nil
	• Loans /advances given (net of provisions, NPAs and sell down portfolio), Debt Securities, other credit extended, etc.		Nil
	• Receivables including interest accrued on Term loan/ Debt		Nil
	• Investment(s)		NIL
	• Cash and cash equivalents and other current/ Non-current assets.		Nil
ii.	Total borrowing through issue of secured Debt Securities (secured by either pari passu or exclusive charge on assets)	B	56.79
	• Debt Securities (Provide details as per table below)		25.00
	• IND - AS adjustment for effective Interest rate on secured Debt		Nil
	• Interest accrued/payable on secured Debt Securities		31.79
iii.	Asset Coverage Ratio (100% or higher as per the terms of offer document/information memorandum/	A/B	NIL

Sr. No.	ISIN	Facility	Type of charge	Sanctioned Amount (Rs. Crores)	Outstanding Amount As On 31 st March 22 (Rs. Crores)	Cover Required (Rs. Crores)	Assets Required (Rs. Crores)
1	INE988W07019	Private Placement of Secured Non-Convertible Debentures	Exclusive	25.00	56.79	56.79	56.79

Table - II

Sr.No	Particulars		Amount
i.	Net assets of the listed entity available for unsecured lenders (Property Plant & Equipment (excluding intangible assets and prepaid expenses) + Investments + Cash & Bank Balances + Other current/ Non-current assets excluding deferred tax assets (-) Total assets available for secured lenders/creditors on pari passu/exclusive charge basis under the above heads (-) unsecured current/ non-current liabilities (-) interest accrued/ payable on unsecured borrowings)	A	NA
ii.	Total Borrowings (unsecured)	B	NA
	Term loan		NA
	Non-convertible Debt Securities		NA
	CC/ OD Limits		NA
	Other Borrowings		NA
	IND - AS adjustment for effective Interest rate on unsecured borrowings		NA



Shankarlal Jain & Associates LLP
Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

iii.	Assets Coverage Ratio (100% or higher as per the terms of Offer Document/Information Memorandum/ Debenture Trust Deed)	(A/B)	NA
------	---	-------	----

c) Compliance of all the covenants/terms of the issue in respect of listed debt securities of the listed entity

We have examined the compliances made by the listed entity in respect of the covenants/terms of the issue of the listed debt securities (NCD's) and certify that such covenants/terms of the issue have been complied by the listed entity.

*Note: The debt is secured against 5,63,497 equity shares of Enaltec Labs Pvt Ltd. cost of which is Rs. 24.89 crores, as per valuation report dated 01.12.2021 the present market value is Rs. NIL.

FOR SHANKARLAL JAIN & ASSOCIATES LLP
CHARTERED ACCOUNTANTS
FIRM REG NO: - 109901W/W100082

SATISH JAIN
Partner

Membership No.: 048874
UDIN : 22048874AIYEOA2428



Place: Mumbai
Date: 13-05-2022